Summary: Background: Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy. The EZH2 inhibitor EPZ-6438 was first approved by the US Food and Drug Administration (FDA) in 2020. However. its inadequate anti-cancer activity in solid tumors limits its clinical application. https://fitnessgravesyardes.shop/product-category/concave-roller/